About us
Company Profile

Citrine Medicine is a therapeutics platform company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. We are dedicated to improving the lives of rare disease patients by making essential treatments available and accessible to those who need them.

Citrine is well positioned to serve the global rare disease community by establishing a patient-centered virtual service platform via digital tools and technology. 

Our goal is to enhance public awareness of rare diseases, help improve screening efficiency, advance early diagnosis, and provide full disease treatment management for patients with rare diseases in China.

Corporate culture
  • Who We Are
  • What We Are Doing
  • How We Work
  • We are dedicated to supporting rare disease patients, doctors and families
  • We are a team of professionals with a strong background in and full commitment to rare disease patients
  • We have the strongest cross-border investor base to establish a significant presence in China for our partners
  • We're building a rare disease ecosystem to bring both a support network and much-needed treatments to individuals and their families affected by rare disease
  • We are developing an integrated platform that can support the scalable commercialization of rare disease drugs in China
  • We build alliance partnerships with companies to bring their products to the China market through business development collaborations
  • We help partners capitalize on the rare disease platform made available by Citrine

Building The First Rare Disease Ecosystem In China.
Enabling Extraordinary People To Live More Ordinary Lives.

Executive leadership

The executive team has extensive experience in building biotech companies, enabling cross border transactions and developing drugs for the U.S. and China markets; as well as deep rare disease, regulatory, medical affairs and commercial operations experience.

  • Shawn Xiang


    • 15+ years’ experience in healthcare and pharmaceutical industries
    • Former GM of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led the team successfully created an ecosystem for patients living with type 1 diabetes, a rare disease impacting 1/100,000 people in China
    • Former Bone Disease Franchise Head and Respiratory Franchise Head at Novartis in China
    • Former Director of Global Pharma Strategy at Novartis global headquarters in Switzerland
    • Former management consultant with McKinsey in the USA
    • Holding a PhD degree from Yale University and a BS degree from Peking University
  • Melissa Bradford-Klug

    Chief Business Officer & President of Citrine Medicine USA

    • 15+ years’ experience in strategic planning and business development
    • Execution on more than $5 billion in deals, ranging from licensing, mergers & acquisitions, option arrangements, joint ventures to divestments
    • Deep and extensive background in evaluating drug development programs, with a focus on rare diseases and orphan drugs
    • In-licensed three drug development programs in the women’s health field
    • Successfully shaped company strategy by diversification through business development and acquisitions
    • Completed B.S. degree in chemistry and earned her MBA with an emphasis on finance from DePaul University
    • Serves on Board of Directors at MassBio
  • Eileen Li

    VP, Head of Corporate Development and Marketing

    • Principal and Lead of IQVIA’s rare disease initiatives
    • 10 years of experience in rare disease space in China & APAC for policy shaping and advocacy
    • Senior Consultant of Chinese Organization for Rare Disorders (CORD)
    • Director of Asia Pacific Alliance of Rare Disease
    • Consultant, Int’l Rare Disease Res Consortium
    • Health economics, Novartis, USA
    • MS from Columbia U, BS from Renmin University
  • Andy Zhang

    VP, Head of Finance

    • 15 years of finance leadership experience in pharma industry across commercial, development, and manufacturing functions
    • Former BPA Head, Novartis China
    • Former Global Development BPA Director & former Group BPA Director, Novartis Global
    • Former Manufacturing and commercial FP&A, Roche China
    • Former Auditor, Deloitte
    • BS from Fudan University
Board of Directors
  • Mahendra G. Shah

    Board Member

    Mahendra G. Shah, Ph.D. is a managing director of Vivo Capital. He also serves as a member of board of directors. Dr. Shah is the founder and executive chairman of Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals Inc.). Dr. Shah previously served as a board member of the Soleno therapeutics Inc, Crinetics Pharmaceuticals, Verona Pharma PLC and Homology Medicines, Inc. From September 2005 to December 2009, he was the founder, chairman and CEO of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was acquired by Pfizer. From 1993 to May 2003, he was the chairman and CEO of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company before it was sold to Shionogi Pharmaceuticals. From 1991 to October 1999, he was vice president of E. J. Financial Enterprises, Inc., a healthcare fund management company. From 1987 to 1991 he was the senior director of new business development with Fujisawa USA (Astellas). Prior to that, he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. 

    Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his B.A. and M.S in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

  • Dandan Dong

    Board Member

    Dandan Dong, Ph.D., is a managing director of Vivo Capital with a background in academic biomedical science research and translational medicine. She has more than ten years’ experience in healthcare investments in both the United States and China. As a key member of Vivo’s cross-border strategy, she has been involved in multiple transactions in both countries and cross-border deals. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle.

    She was involved in founding multiple biotech companies, including VISEN Pharmaceuticals, where she serves as the chief business officer, Joint Development Committee member and board member. She co-founded Citrine Medicine and serves as a board member and a Transaction Committee member.

    Dr. Dong has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.

  • Chong Xu

    Board Member

    Chong Xu, Ph.D., is a principal at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in the U.S. and in China, such as Innovent Biologics and Semma Therapeutics, among others. Prior to joining F-Prime in 2015, Chong was a consultant in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

    Dr. Xu holds a Ph.D. in cell biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

  • Rebecca Lin

    Board Member

    Ms Rebecca Lin is a Senior Partner of Eight Roads (formerly Fidelity Growth Partners Asia), leading the firm’s ventures investments in the healthcare sector in China. Prior to joining Eight Roads in 2007, Rebecca worked for about ten years in venture capital, auditing and management consulting. While working for Vision Capital China and CMT ChinaValue Capital Partners L.P., she focused on venture capital investments in IT and healthcare sectors. Before that, she held positions at A.T Kearney's New York office and Arthur Andersen's Shenzhen office.

    Rebecca has an MBA degree from the Wharton School of Business at the University of Pennsylvania, and a Bachelor’s degree in Economics from Shenzhen University. 

  • Marietta Wu

    Board Member

    Marietta Wu, Ph.D., is a managing director of Quan Capital. She is a founding member of Zai Lab and served as COO and Director of the company prior to Quan Capital. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was managing director at Burrill & Company, leading Burrill’s investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference. Prior to her focus on healthcare investments and company building, Dr. Wu was director of strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company.

    Dr. Wu serves on the board of Citrine Medicine, Crescendo Biologics, Eluminex Biosciences, Innoforce, MEDx Translational Medicine and Zidan Medical. She was a board member of Zai Lab Limited (NASDAQ: ZLAB), Kira Pharmaceutical, Jing Medicine Technology, Taiwan Liposome Company (GTSM: 4152), JHL Biotech (TWEM: 6540), and General Biologics Corporation (TWEM: 4117).

    Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in medical sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

  • Vivo Capital

    Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has...【LEARN MORE】

    Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has $4.3 billion in assets under management, invested in over 250 public and private companies worldwide. Vivo is headquartered in Palo Alto, California, with additional offices in Asia. The Vivo team consists of more than 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives and industry experts. Vivo provides a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices and healthcare services, with a focus on the largest healthcare markets.

  • F-Prime Capital

    F-Prime Capital is a global venture capital firm investing in healthcare and technology...【LEARN MORE】

    F-Prime Capital is a global venture capital firm investing in healthcare and technology.  For the past 50 years, the firm’s independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. With over two billion dollars under management and a global portfolio of more than 200 companies, F-Prime Capital champions those dedicated to creating positive change in the world. F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com.

  • Eight Roads

    Eight Roads is a global proprietary investment firm backed by Fidelity. The flexible nature of...【LEARN MORE】

    Eight Roads is a global proprietary investment firm backed by Fidelity. The flexible nature of its capital means Eight Roads can back and build innovative and ambitious businesses looking to disrupt or lead their chosen markets. Today, Eight Roads and its associated funds across the Fidelity platform constitute one of the top 10 largest sources of venture capital globally. Its global ecosystem offers a tremendous talent pool and source of domain expertise for our founders’ businesses.  

    Eight Roads has over 20 years of venture capital experience in China and has supported over 100 companies in the country’s healthcare and technology sectors. In the past 10 years, the Eight Roads ecosystem has invested almost US $6 billion globally. 

  • Quan Capital

    Quan capital is a life sciences venture capital firm with strong China expertise and global...【LEARN MORE】

    Quan Capital is a life sciences venture capital firm with strong China expertise and global capabilities. The company discovers, incubates, and grows next-generation life science companies in early and growth stage, worldwide. Quan Capital’s portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. Quan has offices in Shanghai, Palo Alto and Boston. Its investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and they leverage their broad network worldwide to help maximize the company’s value across geographies and development stages.

  • 3H Health Investment

    3H Health Investment focuses on healthcare investment to support biomedical...【LEARN MORE】

    3H Health Investment focuses on healthcare investment to support biomedical innovation that can save lives and improve patients' quality of life. With their extended clinical and industry network in China, 3H Health partners with entrepreneurs to build great companies.

  • WU Capital

    Wu Capital is a pioneer family office in Mainland China established in 2013. We take a global...【LEARN MORE】

    WU Capital is a pioneer family office in mainland China established in 2013. It takes a global perspective and develops long-term relationships with top tier fund managers and entrepreneurs worldwide. By leveraging deep understanding of local market landscapes and global networks, WU Capital is  committed to helping entrepreneurs across numerous functions and building syndicates with investors and strategic partners to navigate the complexities in the evolving market.